Results 61 to 70 of about 20,263 (262)

Two-year efficacy of varenicline tartrate and counselling for inpatient smoking cessation (STOP study): A randomized controlled clinical trial.

PLoS ONE, 2020
IntroductionVarenicline tartrate is superior for smoking cessation to other tobacco cessation therapies by 52 weeks, in the outpatient setting. We aimed to evaluate the long-term (104 week) efficacy following a standard course of inpatient-initiated ...
Kristin V Carson-Chahhoud, Brian J Smith, Matthew J Peters, Malcolm P Brinn, Faisal Ameer, Kuljit Singh, Robert Fitridge, Simon A Koblar, Jim Jannes, Antony J Veale, Sharon Goldsworthy, Khin Hnin, Adrian J Esterman   +12 more
doaj   +1 more source

VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES – FRIEND OR ENEMY?

Рациональная фармакотерапия в кардиологии, 2015
The problem of varenicline use in patients with cardiovascular diseases is discussed. Results of large clinical trials and meta-analyses with varenicline have proven its high efficacy for treatment of nicotine addiction in adults and a small number of ...
Yu. V. Lukina, S. Yu. Martsevich
doaj   +3 more sources

Varenicline is More Effective than Nicotine Replacement Therapy During Pregnancy: Findings from the Smoking MUMS (Maternal Use of Medications and Safety) Study

International Journal of Population Data Science, 2018
Introduction Studies in the general population suggest that varenicline is more effective than nicotine replacement therapy (NRT) for smoking cessation.
Stephanie KY Choi, Duong T Tran, David B Preen, Deborah Randall, Anna Kemp-Casey, Kristjana Einarsdottir, Louisa R Jorm, Alys Havard   +7 more
doaj   +1 more source

Varenicline: A new pharmacotherapy for smoking cessation in primary care practice

South African Family Practice, 2011
Background: Cigarette smoking causes significant morbidity and mortality and is a major public health concern worldwide. Primary care doctors are in a unique position that enables them to promote smoking cessation, as smokers are more aware of their ...
N. Robson
doaj   +1 more source

Nicotine addiction : a review [PDF]

, 2013
Nicotine, the major psychoactive compound in tobacco, acts as a potent addictive drug in humans. The addictive nature of nicotine leads to more than 6 million deaths a year.
Di Giovanni, Giuseppe, Vella, Jacob
core   +1 more source

Impact of the disruption in supply of varenicline since 2021 on smoking cessation in England: A population study

Addiction
Background and aims Varenicline is one of the most effective smoking cessation treatments. Its supply in England was disrupted in July 2021 due to nitrosamine impurities found by its supplier, Pfizer.
Sarah E. Jackson, Jamie Brown, Harry Tattan-Birch, L. Shahab   +3 more
semanticscholar   +1 more source

Alcohol use disorder severity moderates clinical response to varenicline.

Alcoholism: Clinical and Experimental Research, 2021
BACKGROUND In a multisite clinical trial, varenicline was effective in reducing drinking in both smoking- and nonsmoking patients with alcohol dependence.
S. Donato, ReJoyce Green, L. Ray
semanticscholar   +1 more source

Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation

Preventive Medicine Reports, 2015
Objectives: A recent trial showed the clinical benefit of retreatment with varenicline in subjects failing on the initial treatment, or relapsing after initial success.
Lieven Annemans, Sophie Marbaix, Kristiaan Nackaerts, Pierre Bartsch   +3 more
doaj   +1 more source

Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the "real world" [PDF]

, 2014
It is important to know the comparative effectiveness of varenicline and nicotine replacement therapy (NRT) for smoking cessation when prescribed under routine circumstances and in the general population. Previous estimates relied on cross-sectional data.
Brown, J, Kotz, D, West, R
core   +1 more source

High‐ and low‐dose topiramate for the treatment of persons with alcohol use disorder who smoke cigarettes: A randomized control trial

Alcohol, Clinical and Experimental Research, EarlyView.
Participants (n = 236) from three sites were randomly assigned to either placebo, low‐dose topiramate (up to 125 mg/day), or high‐dose topiramate (up to 250 mg/day) for up to 18 weeks. Exploratory analyses indicated that participants treated with the high dose had lower mean percentage of heavy drinking days and drinks per day than those taking the low
Jason D. Robinson, Robert M. Anthenelli, Paul M. Cinciripini, Maher Karam‐Hage, Yong Cui, George Kypriotakis, Nassima Ait‐Daoud Tiouririne   +6 more
wiley   +1 more source